About GenIbet
GenIbet is a company based in Oeiras (Portugal) founded in 2006 was acquired by Recipharm in February 2022. GenIbet offers products and services including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing. GenIbet operates in a competitive market with competitors including Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG, among others.
- Headquarter Oeiras, Portugal
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Recipharm Ab
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of GenIbet
GenIbet offers a comprehensive portfolio of products and services, including Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing.
Production of biologics for drug development and therapies
Creation of RNA therapies and lipid nanoparticles
Final processing of advanced therapy medicinal products
Production of plasmid DNA for genetic applications
Funding Insights of GenIbet
Investors in GenIbet
GenIbet has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Recipharm and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability
|
Locked | Locked | Locked | |
|
Pharmaceutical development and manufacturing services are offered contractually.
|
Locked | Locked | Locked |
Investor details for GenIbet
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GenIbet
Investment portfolio details for GenIbet
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GenIbet
Detailed financials for GenIbet
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Genibet Comparisons
Peer comparison for GenIbet
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GenIbet
GenIbet operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bionova Scientific, Avid Bioservices, Just Biotherapeutics, JHL Biotech and ProBioGen AG, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Mammalian cell culture biologics are developed through contract research services.
|
|
| Locked | Locked | Locked |
Drug substance development, analytical, and compliance services are provided.
|
|
| Locked | Locked | Locked |
Designing technologies to accelerate biotherapeutic development and to reduce manufacturing costs
|
|
| Locked | Locked | Locked |
Contract manufacturing solutions for biologics are provided to Asian companies.
|
|
| Locked | Locked | Locked |
Contract development and manufacturing organization focussed on therapeutic proteins/antibodies, viral vaccines and biosimilars
|
|
| Locked | Locked | Locked |
Biologics CDMO specializing in mammalian cell line based manufacturing
|
Detailed competitors of GenIbet
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Genibet
Complete news archive for GenIbet
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GenIbet
GenIbet was founded in 2006 and raised its 1st funding round 9 years after it was founded.
GenIbet is headquartered in Oeiras, Portugal.
Raquel Fortunato is the current CEO of GenIbet.
GenIbet was established in 2006 in Oeiras, Portugal, within the biotechnology sector. Microbial and mammalian-derived products are created through specialized services such as cell line development, process development, and analytical development. Manufacturing activities cover mammalian and insect cells, recombinant proteins, viruses, and biomass from bacteria or yeast. Operations remain focused on biopharmaceutical production and research support in Europe.
GenIbet's top competitors include Avid Bioservices, Bionova Scientific and Rentschler Biopharma.
GenIbet offers Biologics Manufacturing, RNA Manufacturing, ATMP Fill and Finish, and Plasmid Manufacturing.
GenIbet has 2 investors. Key investors include Recipharm, and European Union.